The Galanin System in Cancer
- 17 July 2010
- book chapter
- Published by Springer Nature
- Vol. 102, 223-241
Abstract
Many tumours of neuroendocrine origin, and also an increasing number of non-neuroendocrine cancers, have been shown to express neuropeptides and/or their corresponding receptors. These peptides and receptors represent the molecular basis for in vivo diagnostic or therapeutic targeting of cancer with radiolabelled or cytotoxic peptide analogues. Galanin is a classical neuropeptide that functions in diverse physiological processes such as food intake, nociception, and blood pressure regulation, and it can also act as a growth factor for neurons. Expression of galanin peptide has been detected in pheochromocytoma, pituitary adenoma, neuroblastic tumours, gastrointestinal cancer, squamous cell carcinoma, brain tumours, melanoma, breast cancer and embryonal carcinoma. In several cancers and tumour cell lines expression of galanin receptors – three are known (GalR1, 2 and 3) – has been shown as well. Expression of peptide or receptors has been correlated with tumour stage or subtypes of pituitary adenoma, neuroblastic tumours, colon carcinoma and squamous cell carcinoma. Galanin treatment has tumour-reducing effects in murine models of gastrointestinal cancer, whereas in animal experiments on adenoma formation, galanin seems to act as a growth factor, promoting both proliferation and tumour formation. In cell culture experiments on tumour cell lines, galanin has shown growth promoting or inhibiting effects. Activation of GalR1 is generally anti-proliferative, whereas activation of GalR2 can have pro- or anti-proliferative effects. Therefore, galanin and its receptors are promising targets for diagnosis and treatment of several types of tumours.Keywords
This publication has 91 references indexed in Scilit:
- An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cellsProceedings of the National Academy of Sciences, 2009
- Galanin Receptor Subtype 2 Suppresses Cell Proliferation and Induces Apoptosis in p53 Mutant Head and Neck Cancer CellsClinical Cancer Research, 2009
- Epigenetic Inactivation of Galanin Receptor 1 in Head and Neck CancerClinical Cancer Research, 2008
- Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2)Proceedings of the National Academy of Sciences, 2008
- Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysisJournal of Zhejiang University-SCIENCE B, 2007
- Receptors for luteinizing hormone releasing hormone (LHRH) expressed in human non-Hodgkin’s lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207European Journal of Cancer, 2005
- Experimental therapy of human endometrial cancers with a targeted cytotoxic bombesin analog AN-215: Low induction of multidrug resistance proteinsEuropean Journal of Cancer, 2005
- Galanin within the Normal and Hyperplastic Anterior Pituitary Gland: Localization, Secretion, and Functional Analysis in Normal and Human Growth Hormone-Releasing Hormone Transgenic MiceEndocrinology, 1999
- Effect of galanin on growth hormone (GH) response to thyrotropin releasing hormone of rat pituitary gh-secreting adenomatous cells (GH1) in cultureLife Sciences, 1995
- Inhibitory effect of galanin on growth hormone release from rat pituitary tumor cells (GH1) in cultureLife Sciences, 1994